Finally, 10 mutations (ID: pTrh497Ser, p.Tyr819*, pHis1904Arg, p.Gln383*, p.Thr1069fs, p-Leu412_Pro413fs, p.Gly1370Val, p.Pro554_Pro555fs, p.Ser 385fs, and p.Gly429Arg) in TET2 protein were found in eight patients with therapy-related myeloid neoplasms following treatment for BC [63]. This evidence concerns the gene TET2 and breast cancer.